For clinicians
A record nobody had to write.
What was supplied, how it was kept, when each dose left the unit, and what the patient reports, side by side on one screen. Measured where it can be measured, marked reported where it cannot, and never merged into a conclusion about the treatment.
What the research already says
1 in 8
of biologic injectors were not kept within 2 to 8°C throughout transport and home storage. 276 injectors from 50 patients.
Source 1
33.2%
of injectors spent more than a week above 8°C.
Source 1
79%
of insulin temperature logs, in fridges and carried, fell outside the recommended range. 338 patients, 400 logs.
Source 2
None of these patients knew. None of their clinicians could have known.
1. de Jong MJ, Pierik MJ, Peters A et al. Journal of Gastroenterology and Hepatology 2018;33(2):426-430. 276 injectors from 50 patients, about 2.5 million readings. 2. Braune K, Kraemer LA, Weinstein J et al. Diabetes Technology and Therapeutics 2019;21(5):238-244. 338 patients, 400 temperature logs.
Two kinds of information, kept apart.
One is measured and one is reported. They sit next to each other and are never merged into a conclusion about the treatment.
NEXUS AIR
01 / 03
RECORDED BY THE UNIT
Each removal registered, with the time it happened
ASKED OF THE PATIENT
The reason a dose was not taken, chosen from set options
NEXUS AIR
01 / 03
RECORDED BY THE UNIT
Each removal registered, with the time it happened
ASKED OF THE PATIENT
The reason a dose was not taken, chosen from set options
What you would be looking at.
The clinician’s view.
Patient list: Each patient's storage and dosing, in one place, with the week's priorities first.
Screens are illustrative, and all patient names and figures are fictional.
What a fridge knows, what an app is told,
what Nexus records.
- Recorded by Nexus
- Entered by the patient
- Not available
| Nexus | A domestic fridge | A reminder app |
|---|---|---|
| Temperature record | ||
| Source of the dose record | ||
| Cold chain before it arrives | ||
| What triggers a repeat order | ||
Always check the medicine and its label before each dose. Nexus keeps the record, but it does not replace that check.
Nexus keeps the record, but it cannot check the medicine in your hand. Read the instructions that came with your medicine, and speak to your clinician or pharmacist about anything to do with your treatment.
Who holds the record, and where?
Who holds the record
The patient holds it. They set who can see it, at three levels, and can withdraw that at any time.
Where it is hosted
UK hosted. Placeholder for the hosting and data residency statement, wording from VP.
What reaches you
Only the patients who have shared with your clinic, and only what they have shared.
Export
Per patient and across the cohort, whenever you want it.
Four roles, one record
The clinician, the patient, the pharmacy and the care team each hold part of the picture, and none can see the rest. Nexus gives all four the same record, with nothing re-keyed or self-reported.
- 01
Prescribed
- 02
Replenished
- 03
Supplied
- 04
Seen by the care team
- 05
Placed in the unit
- 06
Recorded
- 07
Held in range
- 08
Registered as it leaves
Credentials
Checkable, not claimed.
Each item displayed is a matter of public record or a signed document.
HOW TO READ THIS
Filed
An application is filed. It is not granted.
Classified
The device class is determined. Conformity is self-declared for Class I.
Signed
An executed document exists.
Planned
The programme is scheduled, with dates set.
- Concept award
Red Dot Design Concept
2026 cycle. Awarded on the design of the unit.
- Classified
UK regulatory status
Classified Class I under UK MDR 2002, following a UK regulatory strategy delivered by RQM+. Conformity is self-declared for Class I.
- Filed
Patent applications
Filed in the UK, the US and internationally.
- Filed
UK trade mark
Application filed with the IPO.
- Signed
Letters of intent
Executed with named partner organisations.
- Appointed
Clinical advisory board
Named clinicians. Full list further down this page.
- Planned
Pilot programme
A fully funded pilot programme, running from June to August 2027. Expressions of interest close on 1 January 2027.
Our People
Company advisory board.
Francesca Howard
Founder & CEO
Sean Mooney
CFO
Jodie Bridge
Marketing and Partnerships Lead
Trisha Durant
Strategic Adviser, Commercial
Dr Cem Baydar
Strategic Adviser, Investment
Four ways
to be a part of this.
- 01
Advise
A seat on the clinical advisory board, unpaid, named with your consent. Four meetings a year, and the product changes because of them.
- 02
Pilot
100 patients across the programme, for 12 weeks from June 2027, funded by us, with the record coming back to you.
- 03
Register interest
Tell us roughly how many of your patients a Nexus device would suit. Non-binding, no price, no deposit. It tells us where to start.
- 04
Back it
If you would rather back it than use it, the deck is on the investors page.
Bring Nexus to your patients
Private hospitals and clinics. Say what you would want to see, and we will send it. A person reads these, and replies.